4.6 Article

Acute interstitial nephritis due to deferasirox: a case report

Journal

NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 23, Issue 10, Pages 3356-3358

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfn423

Keywords

acute interstitial nephritis; deferasirox; iron chelation

Ask authors/readers for more resources

Deferasirox is a new oral iron chelator used to treat transfusional iron overload. Pre-marketing clinical trials revealed little organ-specific toxicity. Increases in serum creatinine were noted in one-third of patients but were mild and non-progressive. We describe a 62-year-old man with myelodysplastic syndrome who developed a progressive decline in renal function after starting deferasirox. A kidney biopsy showed acute interstitial nephritis with increased eosinophils, suggesting drug hypersensitivity. Deferasirox was discontinued and renal function returned to baseline. This is the first pathological description of deferasirox-related acute kidney injury in humans, which differs from tubular vacuolization observed in animals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available